Center for Microbiome & Human Health, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Department for Cellular & Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Nat Rev Cardiol. 2019 Mar;16(3):137-154. doi: 10.1038/s41569-018-0108-7.
Advances in our understanding of how the gut microbiota contributes to human health and diseases have expanded our insight into how microbial composition and function affect the human host. Heart failure is associated with splanchnic circulation congestion, leading to bowel wall oedema and impaired intestinal barrier function. This situation is thought to heighten the overall inflammatory state via increased bacterial translocation and the presence of bacterial products in the systemic blood circulation. Several metabolites produced by gut microorganisms from dietary metabolism have been linked to pathologies such as atherosclerosis, hypertension, heart failure, chronic kidney disease, obesity, and type 2 diabetes mellitus. These findings suggest that the gut microbiome functions like an endocrine organ by generating bioactive metabolites that can directly or indirectly affect host physiology. In this Review, we discuss several newly discovered gut microbial metabolic pathways, including the production of trimethylamine and trimethylamine N-oxide, short-chain fatty acids, and secondary bile acids, that seem to participate in the development and progression of cardiovascular diseases, including heart failure. We also discuss the gut microbiome as a novel therapeutic target for the treatment of cardiovascular disease, and potential strategies for targeting intestinal microbial processes.
我们对肠道微生物群如何促进人类健康和疾病的理解的进展,扩展了我们对微生物组成和功能如何影响人类宿主的认识。心力衰竭与内脏循环充血有关,导致肠壁水肿和肠道屏障功能受损。人们认为这种情况会通过增加细菌易位和细菌产物在全身血液循环中的存在,加剧整体炎症状态。肠道微生物从饮食代谢中产生的几种代谢物与动脉粥样硬化、高血压、心力衰竭、慢性肾脏病、肥胖和 2 型糖尿病等病理有关。这些发现表明,肠道微生物组通过生成生物活性代谢物发挥内分泌器官的功能,这些代谢物可以直接或间接地影响宿主生理。在这篇综述中,我们讨论了几个新发现的肠道微生物代谢途径,包括三甲胺和三甲胺 N-氧化物、短链脂肪酸和次级胆汁酸的产生,这些途径似乎参与了心血管疾病(包括心力衰竭)的发展和进展。我们还讨论了肠道微生物组作为治疗心血管疾病的新型治疗靶点,以及针对肠道微生物过程的潜在策略。